Carfilzomib in multiple myeloma: unraveling cardiac toxicities - from mechanisms to diagnosis and management
The survival rates of patients with hematological malignancies such as multiple myeloma have improved with advances in cancer treatment. However, the risk of cardiovascular disease associated with novel therapeutic agents, including proteasome inhibitors (PIs), is becoming increasingly evident. PIs...
Gardado en:
| Principais autores: | , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Frontiers Media S.A.
2025-03-01
|
| Series: | Frontiers in Pharmacology |
| Assuntos: | |
| Acceso en liña: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1570017/full |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|